| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.0012 | 1 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.0021 | 1 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0014 | 1 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.0013 | 1 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0017 | 1 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.0011 | 1 |
| mRNA | pandacostat | CTRPv2 | pan-cancer | AAC | -0.0009 | 1 |
| mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | 0.0008 | 1 |